ArticleScience translational medicine2021
The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer.
Abstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis.Annals of medicine · 2023Pooled it
- Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner.NPJ precision oncology · 2026Article
- Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation.Molecular therapy. Nucleic acids · 2026Article
- Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors.Nature communications · 2025Article
- FGFR4 promotes CAF activation through the CXCL10-CXCR3 axis in colon cancer.Cell death & disease · 2025Article
- [Clinicopathological characteristics of the CD8Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- In Vitro Transcribed mRNA Immunogenicity Induces Chemokine-Mediated Lymphocyte Recruitment and Can Be Gradually Tailored by Uridine Modification.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Consultation on UTUC II Stockholm 2022: diagnostic and prognostic methods-what's around the corner?World journal of urology · 2023Review
- From mucosal infection to successful cancer immunotherapy.Nature reviews. Urology · 2023Review
- Molecular classification of urothelial bladder carcinoma.Molecular biology reports · 2023Review
- Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8Immunity · 2023Article
- Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013.Asian journal of urology · 2023Article
- Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features.Frontiers in oncology · 2023Article
- Review
- Review
- Upregulation of IFNɣ-mediated chemokines dominate the immune transcriptome of muscle-invasive urothelial carcinoma.Scientific reports · 2022Article
- Establishing Cell Models to Understand Cellular Toxicity: Lessons Learned from an Unconventional Cell Type.Toxins · 2022Review
- Adaptive Immune Receptor Repertoire (AIRR) Community Guide to Repertoire Analysis.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Immune status for monitoring and treatment of bladder cancer.Frontiers in immunology · 2022Review
Corrections and comments
- Commented on by
- Commented on byUro-Science.2021
Authors and funding
21 authors at 5 institutions in 3 countries.
Tino VollmerInstitute of Medical Immunology, Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0002-0358-3876
Stephan SchlickeiserInstitute of Medical Immunology, Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0003-3142-2890
Leila AminiInstitute of Medical Immunology, Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0003-4855-5905
Sarah SchulenbergBerlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0003-3719-6652
Desiree J WenderingInstitute of Medical Immunology, Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.
Viqar BandayDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, 901 85 Umea, Sweden.ORCID 0000-0002-5081-2272
Anke JurischInstitute of Medical Immunology, Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0002-7794-1517
Rebecca NosterBerlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0002-1069-0602
Desiree KunkelBerlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0002-0054-955X
Nicola R BrindleBerlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0001-5406-7241
Ioannis SavidisBerlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.
Levent AkyüzInstitute of Medical Immunology, Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0003-1093-8505
Jochen HechtCentre for Genomic Regulation, Barcelona Institute of Science and Technology, 08003 Barcelona, Spain.
Ulrik StervboCenter for Translational Medicine, Medical Clinic I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, D-44623 Herne, Germany.ORCID 0000-0002-2831-8868
Toralf RochBerlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0003-2948-8700
Nina BabelBerlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.
Petra ReinkeBerlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.ORCID 0000-0003-0771-4375
Ola WinqvistDepartment of Clinical Immunology, Karolinska University Hospital, 17 176 Stockholm, Sweden.
Amir SherifDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, 901 85 Umea, Sweden.ORCID 0000-0002-3675-3050
Hans-Dieter VolkInstitute of Medical Immunology, Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.
Michael Schmueck-HenneresseInstitute of Medical Immunology, Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany. michael.schmueck-henneresse@charite.de.ORCID 0000-0001-5964-9179
Berlin Institute of Health at Charité - Universitätsmedizin Berlin · DEUniversitätsklinik Marien Hospital Herne · DEUmeå University · SEKarolinska University Hospital · SEUniversitat Pompeu Fabra · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy has direct toxic effects on cancer cells; however, long-term cancer control and complete remission are likely to involve CD8
Indexed as
Urinary Bladder NeoplasmsCD8-Positive T-LymphocytesChemokine CXCL10Chemokine CXCL11ChemokinesChemotherapy, AdjuvantHumansNeoadjuvant TherapyReceptors, CXCR3Chemokine CXCL10Chemokine CXCL11ChemokinesCXCR3 protein, humanReceptors, CXCR3
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.